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GPR116 is an orphan seven-pass transmembrane re-
ceptor whose function has been unclear. Global
disruption of the Gpr116 gene in mice revealed an
unexpected, critical role for this receptor in lung sur-
factant homeostasis, resulting in progressive accu-
mulation of surfactant lipids and proteins in the
alveolar space, labored breathing, and a reduced
lifespan. GPR116 expression analysis, bone marrow
transplantation studies, and characterization of con-
ditional knockout mice revealed that GPR116
expression in ATII cells is required for maintaining
normal surfactant levels. Aberrant packaging of sur-
factant proteins with lipids in the Gpr116 mutant
mice resulted in compromised surfactant structure,
function, uptake, and processing. Thus, GPR116
plays an indispensable role in lung surfactant ho-
meostasis with important ramifications for the under-
standing and treatment of lung surfactant disorders.INTRODUCTION
The vital process of mammalian breathing requires alveoli to
expand and contract without collapsing, a remarkable feat that
depends upon the surface tension-reducing properties of the
lipid-rich surfactant film that lines the alveolus (Trapnell et al.,
2003). Pulmonary surfactant, which also functions in innate im-
munity, is composed of 90% lipids (primarily phosphatidylcho-
line [PC]) and 10% protein (surfactant proteins A [SP-A], SP-B,
SP-C, and SP-D). In premature infants, insufficient production
of surfactant leads to neonatal respiratory distress syndromeC(RDS). Surfactant deficiency also contributes to the pathogen-
esis of acute lung injury (ALI) and acute RDS (ARDS), disorders
that can afflict patients of all ages and carry a mortality rate
greater than 25% (Lewis and Veldhuizen, 2006; Raghavendran
et al., 2011). Conversely, accumulation of surfactant in the alve-
olar space leads to pulmonary alveolar proteinosis (PAP) (Carey
and Trapnell, 2010). Although important progress has been
made in understanding surfactant catabolism by macrophages,
a process dependent upon GM-CSF signaling (Carey and Trap-
nell, 2010; Sakagami et al., 2009), mechanisms regulating
surfactant homeostasis in the alveolar space remain largely un-
explained. Furthermore, whole-lung lavage, the standard of
care for PAP, only helps a subset of patients, has numerous
complications, and does not address the pathogenic mecha-
nisms at work (Borie et al., 2011). Thus, new methods of regu-
lating surfactant levels and activity are urgently needed and
could have an impact on a myriad of lung diseases.RESULTS AND DISCUSSION
Genetic Disruption of Gpr116 Results in a Shortened
Lifespan Associated with Pulmonary-Specific
Abnormalities
G protein-coupled receptor (GPCR) superfamily members
mediate cell signaling in response to a diverse array of extracel-
lular stimuli and comprise over one-third of the drug targets of
modern medicine (Tang et al., 2012). While searching a large
panel of gene expression libraries for endothelial GPCRs (Sea-
man et al., 2007; St Croix et al., 2000), we identified Gpr116,
also called Ig-Hepta in rats (Abe et al., 1999), as a pan-endothe-
lial-expressed gene of unknown function (Figures S1A–S1H; see
also Wallgard et al., 2008). Gpr116 was broadly expressed in
normal unfractionated tissues with highest expression in lungell Reports 3, 1457–1464, May 30, 2013 ª2013 The Authors 1457
Figure 1. Gpr116 Is Expressed in Lung ECs and ATII Cells and Is Important for Maintaining Lung Surfactant Homeostasis
(A) Survival analysis of Gpr116 WT and KO mice.
(B) An accumulation of eosinophilic, SP-A+ material was observed in the alveolar space of 6-month-old lungs of KO mice by H&E and SP-A staining. Scale bar,
50 mm.
(C) The accumulated lung material stained positive with oil red O dye indicative of a buildup of neutral lipids in the alveolar space. Scale bar, 50 mm.
(D) Immunoblotting for SP-A, SP-B, SP-C, and SP-D in KO versus WT whole-lung lysates.
(E) Immunohistochemical staining of normal human lung. GPR116 protein (red) can be found in both ECs and ATII cells (arrows in inset), whereas alveolar
macrophages were negative (yellow arrowheads). Scale bar, 100 mm.
(legend continued on next page)
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(Abe et al., 1999) (Figure S1C). To explore the function of
GPR116, we generated Gpr116/ knockout (KO) mice by
removing exon 2 containing the start codon and signal peptide
(Figures S1I–S1L). Gpr116 KO mice were viable and fertile but
displayed labored breathing by 4 months of age, weighed up
to 25% less than wild-type (WT) littermates by 14 months, and
had a shortened lifespan (Figures 1A and S2A). A complete his-
topathological survey of 6-month-old mice revealed defects only
in the KO lung, whereas heterozygousmice were normal. A PAP-
like phenotype was observed in the KO, which included a striking
accumulation of eosinophilic, periodic acid-Schiff (PAS)-positive
material in the alveolar space (Figures 1B and S2B). Oil red O
staining confirmed the buildup of lipids in the alveolar material
that also stained positive for SP-A by immunohistochemistry
(Figures 1B and 1C). Immunoblotting showed a large increase
in SP-A and SP-B and a smaller increase in SP-C and SP-D in
Gpr116KO lung samples (Figure 1D). Supraphysiologic accumu-
lation of alveolar SP-A was apparent by 2 weeks of age and
increased with time (Figures 1D and S2C).
To better understand GPR116 protein expression patterns, we
performed immunohistochemical staining of human lung tissues.
GPR116 was strongly expressed in lung endothelial cells (ECs)
that lined blood-filled vessels (Figure 1E), consistent with the
earlier mRNA expression analysis (Figure S1C). GPR116 protein
was also detected in sporadic epithelial cells lining the alveoli
(Figure 1E, arrows) that were subsequently identified as ATII cells
based on SP-B coimmunofluorescence staining (Figure 1F).
Clara cells did not stain (Figure S2D). QPCR analysis confirmed
Gpr116 expression in both ATII cells and ECs isolated from mu-
rine lung (Figure 1G).
Bronchoalveolar lavage fluid (BALF) had amilky appearance in
the Gpr116 KO (Figure 2A), similar to that observed in patients
with PAP (Trapnell et al., 2003). An analysis of the BALF lipid con-
tent at 3 months revealed an 8-fold increase in PC (Figure 2B)
and a 13-fold increase in cholesterol, the most abundant neutral
lipid in surfactant, even though blood cholesterol levels were not
significantly altered (Figure S2E). H&E of BALF cytospins
revealed numerous enlarged foamy macrophages that were oc-
casionally multinucleated (Figure 2C). By ultrastructural micro-
scopy, alveolar spaces of the KO lungs showed an excessive
number of multilamellated structures that resembled the intracy-
toplasmic inclusions, or lamellar bodies (LBs) of ATII cells
(Figure 2D). Furthermore, macrophages were loaded with sur-
factant-laden phagosomes and frequently contained cholesterol
clefts (Figure 2E). Thus, Gpr116 KO mice display many of the
phenotypic hallmarks of human PAP.
Lung Defects in Global Gpr116 KOMice Are Not Caused
by Loss of GPR116 in ECs or Macrophages
The normal alveolus is lined by ATI and ATII epithelial cells that
are separated fromECs by a basementmembrane. To determine
if GPR116+ ECs influence surfactant levels indirectly, perhaps(F) Immunofluorescence staining of normal human lung. GPR116 protein (red) co
(G) QPCR analysis was used to assess Gpr116 expression in unfractionated lun
specific markers were used to verify enrichment of isolated macrophages (Em
represent SD.
See also Figures S1 and S2.
Cthrough paracrine regulation of neighboring ATII cells or
macrophages, we generated Gpr116 conditional KO mice
(Gpr116/flox, Tie2-Cre) that contain a Gpr116 ‘‘floxed’’ allele
and Cre driven by the Tie2 promoter that results in deletion in
ECs and a fraction of hematopoietic cells. No defects were
observed despite efficient deletion of Gpr116 in lung ECs (Fig-
ures S3A–S3D). These results suggest that a non-EC type may
be responsible for driving the global Gpr116 KO phenotype.
Autoimmune PAP is caused primarily by defects in GM-CSF
signaling that result in defective catabolism of surfactant by alve-
olar macrophages (Borie et al., 2011; Carey and Trapnell, 2010).
Todetermine ifGM-CSFsignaling inmacrophageswasperturbed
in the Gpr116 KO, we used QPCR to evaluate Csf2 (GM-CSF)
levels and critical downstream components required for macro-
phage differentiation and function including Sfpi1 (PU.1), pparg
(PPARg), andAbcg1 (Malur et al., 2011a; Malur et al., 2011b; Shi-
bata et al., 2001) but did not observe any alterations in expression
(Figures S3E–S3G). Furthermore, neither Gpr116 mRNA nor
GPR116 protein was detected in macrophages (Figures 1E and
1G), and Vav-iCre conditional Gpr116 KO mice that deleted
Gpr116 efficiently in macrophages (Figure S3H) and possibly
other vav+ leukocytes failed to develop a PAP-like phenotype
(Figure S3I). We also performed bone marrow (BM) transplanta-
tion experiments and found that BM from theGpr116KOwas un-
able to transfer thePAP-likedisease toWT recipients (FigureS3J).
Conversely, transfer ofWTGpr116BM into KOmice failed to pre-
vent the accumulation of surfactant (Figure 2F). Moreover, in the
latter experiments, WT macrophages became foamy, enlarged,
andbinucleate, similar to that in theglobalKO (compareFigure2G
with Figure 2C), indicating that the KO lung microenvironment
drives the abnormal macrophage phenotype. Consistent with
this idea, foamymacrophages transplanted fromKO lungs to sur-
factant-free cell culture rapidly reverted to WT size and exhibited
normal phagocytic function (Figure S3K). Based on these data,
we conclude that the PAP-like phenotype in the Gpr116 KO is
not driven by an autonomous macrophage defect but, rather, a
distinct mechanism involving other alveolar cell type(s).
Autonomous Expression of GPR116 in ATII Cells Is
Required for Normal Lung Surfactant Homeostasis
ATII cells produce surfactant and, along with macrophages,
participate in its catabolism (Trapnell et al., 2003). No ultrastruc-
tural abnormalities were observed in ATII cells at 1 month. How-
ever, by 1 year, KO ATII cells displayed mild hyperplasia,
increased LB size, and evidence of LB fusion (Figure S4). To
determine if ATII cells were driving the global KO phenotype,
we generated conditional Gpr116 KO mice containing a floxed
Gpr116 allele and a Cre transgene driven by the constitutive
SFTPC promoter. Interestingly, SFTPC-Cre Gpr116 conditional
KO mice showed a phenotype indistinguishable from the global
null, including amorphous eosinophilic SP-A+ material in the
alveoli (Figure 3A).localizes with SP-B (green). Scale bar, 5 mm.
g tissue, lung ECs, and ATII cells and alveolar macrophages (MØ). Lineage-
r1, encoding F4/80 antigen), ECs (Cdh5), and ATII cells (Sftpa). Error bars
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Figure 2. Foamy Macrophages Result from
Changes in the Alveolar Microenvironment
and Are Not Caused by GPR116 Loss in
Macrophages
(A) Clarity of BALF was evaluated in Gpr116 WT
and KO mice.
(B) PC levels were quantified in KO versus WT
BALF at 3 and 16 months (p < 0.01). Error bars
represent SD.
(C) H&E of BALF from WT and KO mice. Approxi-
mately half of the macrophages in the KO were
enlarged and foamy, and a smaller fraction (3%)
was binucleate (inset). Scale bar, 50 mm.
(D) Ultrastructural analysis of surfactant in the
alveolar space of Gpr116 KO lungs. Scale bar,
10 mm.
(E) Ultrastructural analysis of macrophages with
surfactant-laden phagosomes. Macrophages
contained rod-shaped electron-dense inclusions
(arrows) similar to those in Sftpa transgenic mice
(Elhalwagi et al., 1999), possibly Ym1 crystals, as
well as electron-transparent cholesterol clefts
(arrowheads). Scale bar, 2 mm.
(F) SP-A immunohistochemistry performed on
lungs following BM transplantation. The transfer of
Gpr116 WT BM into KO mice failed to prevent the
accumulation of SP-A+ material in the alveolar
space. Scale bar, 100 mm
(G) Immunofluorescence performed on BALF
following BM transplantation. An accumulation of
enlarged, occasionally binucleate, macrophages
was observed 6 months following the transfer of
WT BM into the KO host. GFP expression of BALF
cells confirms their origin from GFP-positive WT
donor mice. To visualize all BM cells, membranes
were labeled with CellMask Orange (CMO; red)
and nuclei with DAPI (blue). Scale bar, 10 mm.
See also Figure S3.Although the SFTPC promoter is predominantly expressed by
ATII cells in adult mice, during embryogenesis, SFTPC-Cre is
also expressed in early endoderm, leading to permanent Cre-
mediated deletion of floxed genes in all respiratory epithelium
including ATI cells (Okubo et al., 2005). To restrict the deletion
to ATII cells, we further generated doxycycline-inducible
SFTPC-driven Gpr116 conditional KO mice that contained a
floxed Gpr116 allele and both the tetO-Cre and SFTPC-rtTA1460 Cell Reports 3, 1457–1464, May 30, 2013 ª2013 The Authorstransgenes. Following doxycycline induc-
tion, we observed an accumulation of
surfactant in the alveoli of SFTPC condi-
tional Gpr116 KO mice (Gpr116/flox;
Tg(SFTPC-rtTA/tetO-Cre)), but not con-
trol mice that retained a WT Gpr116 allele
(Gpr116/+; Tg(SFTPC-rtTA/tetO-Cre))
(Figure 3B). Furthermore, in the BALF of
the conditional KO, we detected an accu-
mulation of SPA, SP-B, SP-C, and SP-D
by western blotting and an elevation of
PC and cholesterol by ELISA (Figures
3C and 3D), recapitulating each of the
major phenotypes observed in the globalKO. Taken together with the previous GPR116 expression anal-
ysis (Figures 1E–1G and S2D), we conclude that specific loss of
GPR116 expression in ATII cells is responsible for the lung de-
fects observed in global KO mice.
To explore the subcellular location of GPR116, we tagged
GPR116 with GFP (GPR116-GFP) and expressed the fusion pro-
tein in A549 lung cells, a LB-containing cell line derived from ATII
cells (Lieber et al., 1976). GPR116 was found to reside
Figure 3. GPR116 Expression in ATII Cells Is
Important for Lung Surfactant Homeostasis
(A) Surfactant accumulation in the alveolar space
was assessed following constitutive SFTPC-Cre-
mediated deletion. Scale bars, 50 mm.
(B) Surfactant accumulation in the alveolar space
was assessed following doxycycline-inducible
SFTPC-Cre-mediated deletion. Scale bars, 50 mm.
(C) Immunoblotting for SP-A, SP-B, SP-C, and SP-
D in BALF derived from Gpr116/flox conditional
KO mice containing the indicated transgenes.
(D) PC and total cholesterol levels were quantified
in WT versus KO BALF at 1 year of age (n = 3; p <
0.01). Error bars represent SD.
See also Figure S4.predominantly in cytoplasmic vesicles with additional, limited
expression at the cell surface (Figure 4A). This expression
pattern was confirmed by both immunofluorescence (using
GPR116 N-terminal Flag-tagged and C-terminal pyo-tagged
vectors) and cell surface biotinylation studies (data not shown).
Coimmunofluorescence labeling of GPR116 with ABCA3, a re-
ceptor that has been localized to the LB-limiting membrane
(Mulugeta et al., 2002), revealed partial colocalization in LBs (Fig-
ure 4B). Thus, GPR116 resides both in LBs and at the cell sur-
face, consistent with KO abnormalities both in the alveolar space
(Figures 1B, 1C, and S2B) and inside the ATII cell (Figure S4).
GPR116 Is Required for Surfactant Uptake into ATII
Cells
To understand the basis of the alveolar surfactant protein accu-
mulation, we began by evaluating the mRNA levels of surfactant
proteins in isolated ATII cells. We observed either no alteration in
the KO (Sftpb, Sftpc, and Sftpd) or a 50% decrease (Sftpa) in
expression (Figure 4C). Similarly, QPCR failed to detect any in-
crease in expression of genes involved in lipid synthesis or trans-
port in the KO lung, including Abca3, Pcyt1a, Fasn, Gpam,
Hmgcr, and Srebf2 (data not shown). We also failed to detect
any increase in radiolabeled PC in the KO alveolar space
following intravenous injection of 14C-choline into Gpr116 WT
or KO mice (data not shown). Next, we examined SP-A and
SP-B protein levels in isolated ATII cells and detected either no
differences between WT and KO (SP-B) or a decrease in the
KO (SP-A), in striking contrast to the clear increase observed in
KO BALF and total lung lysates (Figure 4D). Furthermore, meta-
bolic labeling of SP-A, the most overexpressed surfactant pro-
tein in the KO, revealed a slightly reduced production by
Gpr116 KO ATII cells (Figure 4E).
Although immunohistochemistry revealed predominant
expression of SP-A in ATII cells ofWT lung, in the KO, SP-A stain-
ing localized predominantly to the alveolar space and was barelyCell Reports 3, 1457–146detectable inside ATII cells (Figure 1B),
suggesting that reuptake into ATII cells
may be impaired. Because individual sur-
factant components were overexpressed
to variable degrees in the KO lung (Fig-
ure 1D), we hypothesized that the altered
surfactant composition could result indefective uptake. We obtained further evidence that surfactant
composition was altered when we found that a polyclonal anti-
SPA antibody that readily immunoprecipitated SP-A from
Gpr116WT lung lavage only immunoprecipitated a small fraction
of SP-A from the KO surfactant (Figure 4F). Importantly, SP-A
immunoprecipitation from the KO was rescued following lipid
extraction of the surfactant with butanol, revealing an abnormal
association of SP-A with lipids that presumably resulted in
epitope masking (Figure 4F). These results suggested that the
phospholipid composition may be altered in the Gpr116 KO.
To investigate this possibility further, we isolated BALF from
either 6-week-old or 6-month-old Gpr116 WT or KO mice and
performed lipidomics analysis using electrospray ionization
mass spectrometry (ESI-MS) (Figures 4G–4J; Tables S1 and
S2) (Ivanova et al., 2007; Myers et al., 2011). These studies re-
vealed that the total amount of phospholipids in the BALF
increased rapidly in Gpr116 KO versus WT mice (5.9-fold by
6 weeks of age) and preceded the large increase in surfactant
proteins that occurred by 6 months of age (Figures 4G–4J). An
analysis of the different surfactant phospholipid classes,
including PC, phosphatidylethanolamine (PE), phosphatidylgly-
cerol (PG), phosphatidylinositol (PI), and phosphatidylserine
(PS), revealed that the total levels of each were significantly
increased in KO BALF, ranging from 4.1-fold (PS) to 9.7-fold
(PI). Modest but significant changes in the ratio of PE, PI, and
PS were also detected by 6 weeks of age (Figure 4I). Further-
more, an analysis of the individual lipid species within each class
revealed an unexpected shift from saturated or monounsatu-
rated fatty acids (FAs) to polyunsaturated FAs (Figure 4J; Table
S1). A significantly increased amount of saturated lysophospho-
lipids was also detected in the KO BALF (Table S2). Further
studies are required to determine if reacylation of lysophospho-
lipids is impaired or degradation of phospholipids by phospholi-
pases is enhanced in the KO. Taken together, these studies
reveal multiple and extensive changes in the phospholipid4, May 30, 2013 ª2013 The Authors 1461
(legend on next page)
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composition of Gpr116 KO surfactant that potentially impact its
biophysical properties.
Next, we sought to determine if the altered surfactant compo-
sition impacts uptake of surfactant proteins or lipids into ATII
cells. First, we isolated equivalent amounts of WT or KO surfac-
tant, spiked it with purified human SP-A, and then monitored
SP-A uptake into freshly isolated ATII cells by immunoblotting
using an anti-human SP-A mouse monoclonal antibody. The
antibody employed does not cross-react with mouse SP-A,
enabling us to track uptake of the exogenous human SP-A pro-
tein without interference from endogenous mouse SP-A. As
shown if Figure 4K, these studies reveal that SP-A/WT surfactant
was taken up by the ATII cells more efficiently than the SPA/KO
surfactant. Next, we labeled the surfactant from WT or KO BALF
with rhodamine and examined uptake into both A549 cells and
GFP-positive ATII cells from SPC-GFP mice. In both models,
WT surfactant was taken up more rapidly than KO surfactant
(Figures 4L and 4M), although uptake into alveolar macrophages
was unaffected. Taken together, these results indicate that
GPR116 plays a role in regulating surfactant uptake by ATII cells,
which is related, at least in part, to an abnormal surfactant as-
sembly and composition.
Here, we provide evidence that GPR116 plays a highly spe-
cific, essential role in lung surfactant homeostasis and provide
a mouse model for studying PAP driven by an autonomous
ATII cell defect. The involvement of a GPCR family member in
surfactant regulation has important implications for the under-
standing and treatment of lung surfactant disorders.
EXPERIMENTAL PROCEDURES
Animals
Mice were housed in a pathogen-free facility certified by the Association for
Assessment and Accreditation of Laboratory Animal Care International, and
the study was carried out in accordance with protocols approved by the NCI
Animal Care and Use Committee. Further details on gene-targeting strategies
and animal experiments are described in Extended Experimental Procedures.Figure 4. Gpr116 Disruption Leads to a Defect in Surfactant Uptake by
(A) GPR116-GFP expression is localized to the cell surface and LB-like structure
(B) Immunofluorescence staining was used to evaluate colocalization of GPR1
colocalization (yellow) in LB-like structures. In this experiment, cells were permea
cell surface. Scale bar, 10 mm.
(C) QPCR analysis of purified ATII cells for SP-A, SP-B, SP-C, and SP-D at 6 we
(D) Immunoblotting of SP-A and SP-B in whole-lung lysates or isolated ATII cells
loading control.
(E) Metabolic labeling of SP-A protein in ATII cells derived from Gpr116 WT and
(F) Immunoprecipitation (IP) of SP-A with rabbit anti-SPA antibodies. Note the effi
immunoblot.
(G) Total protein and total glycerophospholipid (GPL) levels were quantified in BA
(H) Total PC, PE, PG, PI, and PS levels were quantified in BALF from 6-week-old
(I) The relative distribution of GPLs was quantified in BALF from 6-week-old WT
(J) The individual PC specieswere quantified in BALF from 6-week-oldWT or KOm
in their FA chains followed by the number of double bonds in the FA chains.
(K) Purified human SP-A was mixed with surfactant from WT or KO mice, and upt
human SP-A antibodies. b-Actin was used as a loading control.
(L) Uptake of rhodamine-PE-labeled WT or KO surfactant was evaluated in A549
(M) Uptake of rhodamine-PE-labeled WT or KO surfactant was evaluated in A
experiment, GFP-positive ATII cells (green) were not sorted by flow cytometry,
hematopoietic cells and ECs. Scale bars, 5 mm.
Error bars represent SD (C) or SEM (G–J). *p < 0.05, **p < 0.01, ***p < 0.001.
See also Tables S1 and S2.
CHuman Lung Tissues
The anonymized human lung tissue samples were obtained from the Cooper-
ative Human Tissue Network with approval from the NIH Office of Human Sub-
ject Research. Nonmalignant lung tissues were derived from excess lung
material removed at the time of surgical tumor removal. The histological stain-
ing methods are described in Extended Experimental Procedures.
Immunoblotting
Immunoblotting was performed as previously described by Nanda et al. (2004)
using antibodies from Millipore against SP-A (AB3420), SP-B (AB3780), SP-C
(AB3786), and SP-D (AB3434). Additional anti-SPA antibodieswere purchased
from Santa Cruz Biotechnology (sc-7699), Abcam (ab115791), and United
States Biological (S8400-02).
Statistical Analysis
Unless stated otherwise, differences between two groups (for example,
Gpr116WT and KO) were presented as the average ± SEM, and statistical sig-
nificance was calculated using a Student’s t test. For comparisons among
multiple groups, a one-way ANOVA was used with a Bonferroni posttest.
The p values <0.05 were considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, four
figures, and three tables and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2013.04.019.
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